SCHEMBL31677815

SCHEMBL31677815

CCc1c(C)c(=O)n2c(-c3ccccc3N)c(C)nc2n1CC(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ KDR P35968 3/20 0.39
▸ MAPT P10636 3/20 0.39
▸ TP53 P04637 2/20 0.39
▸ AKR1B1 P15121 1/20 0.39
▸ POLB P06746 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ BCHE P06276 1/20 0.37
▸ PTGS1 P23219 1/20 0.37
▸ TRPA1 O75762 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ CACNA1G O43497 1/20 0.36
▸ CACNA1B Q00975 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ FPR1 P21462 1/20 0.36
▸ FPR2 P25090 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31678841 0.87 MAPT (0.39) KDM4EKMT2AKDRMAPTTP53
SCHEMBL31678761 0.86 MAPT (0.40) KDM4EKMT2AKDRMAPTTP53
SCHEMBL31677806 0.85 AKR1B1 (0.40) KDM4EKMT2AKDRMAPTTP53
SCHEMBL31678803 0.85 MAPT (0.39) KDM4EKMT2AKDRMAPTTP53
SCHEMBL31678252 0.84 KDM4E (0.40) KDM4EKMT2AKDRMAPTTP53
SCHEMBL31677885 0.83 KDM4E (0.43) KDM4EKMT2AKDRMAPTTP53
SCHEMBL31677705 0.81 KMT2A (0.41) KDM4EKMT2AMAPTTP53MEN1
SCHEMBL31664583 0.79 MAPT (0.41) KDM4EKMT2AKDRMAPTTP53
SCHEMBL31678727 0.78 AKR1B1 (0.41) KDM4EKMT2AKDRMAPTTP53
SCHEMBL31678760 0.76 KDM4E (0.43) KDM4EKMT2AKDRMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS INCYTE CORPORATION (US) 2025-08-28 — — US disclosed
US-20250270218-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS INCYTE CORPORATION (US) 2025-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS WRN, RECQL, BLM KDM4E 2390/4885KMT2A 1697/4885KDR 3379/4885
US-20250270218-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS WRN, RECQL, BLM KDM4E 3187/4885KMT2A 2415/4885KDR 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback